Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery

• Status: Completed
• Trial end date: 2024-05-15
• Target enrollment: 0
• Participant gender: All

Summary

This is a multicenter, double-masked, randomized, vehicle-controlled, parallel-comparison study conducted at sites in the United States (US) in subjects undergoing routine unilateral cataract extraction and lens replacement (CELR) surgery via phacoemulsification

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: VivaVision Biotech, Inc
• Treatments: Ophthalmic Solutions; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• ≥21 years of age and in good general health at Visit 1 (Screening)

• Willing and able to provide informed consent and provide relevant privacy authorization(s)

• Willing and able to comply with study requirements and visit schedule

• Clear ocular media (other than cataract) in the study eye

• Planning to undergo routine unilateral cataract surgery via phacoemulsification extraction and implantation of an intraocular lens.

Exclusion Criteria:

• Any ocular pain at Visit 1 (Screening)

• Recent use of corticosteroids or oral non-steroidal anti-inflammatory drugs